Primary Synchronous Lung Cancer Detected using Autofluorescence Bronchoscopy.
10.4046/trd.2006.60.6.645
- Author:
Sun Jung KWON
1
;
Yun Seun LEE
;
Mi Kyong JOUNG
;
Yu Jin LEE
;
Pil Soon JANG
;
Jeung Eyun LEE
;
Chae Uk CHUNG
;
Hee Sun PARK
;
Sung Soo JUNG
;
Sun Young KIM
;
Ju Ock KIM
Author Information
1. Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Korea. jokim@cnu.ac.kr
- Publication Type:Original Article
- Keywords:
Autofluorescence bronchoscopy;
Premalignant lesions;
Synchronous lung cancer
- MeSH:
Biopsy;
Bronchoscopy*;
Carcinoma, Non-Small-Cell Lung;
Humans;
Lung Neoplasms*;
Lung*;
Prevalence;
Radiotherapy;
Small Cell Lung Carcinoma
- From:Tuberculosis and Respiratory Diseases
2006;60(6):645-652
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: Patients with lung cancer have a relative high risk of developing secondary primary lung cancers. This study examined the additional value of autofluorescence bronchoscopy (AFB) for diagnosing synchronous lung cancers and premalignant lesions. METHODS: Patients diagnosed with lung cancer from January 2005 to December 2005 were enrolled in this study. The patients underwent a lung cancer evaluation, which included white light bronchoscopy (WLB), followed by AFB. In addition to the primary lesions, any abnormal or suspicious lesions detected during WLB and AFB were biopsied. RESULTS: Seventy-six patients had non-small cell lung cancer (NSCLC) and 23 had small cell lung cancer (SCLC). In addition to the primary lesions, 84 endobronchial biopsies were performed in 46 patients. Five definite synchronous cancerous lesions were detected in three patients with initial unresectable NSCLC and in one with SCLC. The secondary malignant lesions found in two patients were considered metastatic because of the presence of mediastinal nodes or systemic involvement. One patient with an unresectable NSCLC, two with a resectable NSCLC, and one with SCLC had severe dysplasia. The detection rate for cancerous lesions by the clinician was 6.0% (6/99) including AFB compared with 3.0% (3/99) with WLB alone. The prevalence of definite synchronized cancer was 4.0% (4/99) after using AFB compared with 2.0% (2/99) before, and the staging-up effect was 1.0% (1/99) after AFB. Since the majority of patients were diagnosed with advanced disease, the subjects with newly detected cancerous lesions did not have their treatment plans altered, except for one patient with a stage-up IV NSCLC who did not undergo radiotherapy. CONCLUSIONS: Additional AFB is effective in detecting early secondary cancerous lesions and is a more precise tool in the staging workup of patients with primary lung cancer than with WLB alone.
